Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 5.93B |
| Revenue (ttm) | 776.62M |
| Net Income (ttm) | -384.77M |
| Shares Out | 145.97M |
| EPS (ttm) | -2.67 |
| PE Ratio | n/a |
| Forward PE | 90.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,329,067 |
| Open | 41.18 |
| Previous Close | 41.12 |
| Day's Range | 40.43 - 41.31 |
| 52-Week Range | 35.95 - 54.44 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 59.36 (+46.03%) |
| Earnings Date | Aug 7, 2024 |
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen ... [Read more]
Financial Performance
In 2023, IONS's revenue was $787.65 million, an increase of 34.10% compared to the previous year's $587.37 million. Losses were -$366.29 million, 35.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $59.36, which is an increase of 46.03% from the latest price.
News
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; cont...
Ionis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRNewsw...
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Scleros...
Biogen, Ionis to discontinue development of ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patie...
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis conti...
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivot...
Ionis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ge...
Ionis reports first quarter 2024 financial results
WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; p...
Ionis Publishes 2023 Corporate Responsibility Report
Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring ...
Ionis to hold first quarter 2024 financial results webcast
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – ...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. , April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23...
Ionis to hold olezarsen Phase 3 data webcast
Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif.
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute pancreatitis events in patients with rare, life-threatening disease, for whic...
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of a mid-stage trial.
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Significant improvement in steatohepatitis with > 2 point improvement in NAS score without worsening fibrosis, the primary endpoint of the study Achieved key secondary endpoint of MASH resolution with...
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Kyle Jenne rejoins company to lead commercial strategy Onaiza Cadoret-Manier departing for new career opportunity With broad commercial capabilities in place, Ionis ready to execute on its first inde...
Ionis reports fourth quarter and full year 2023 financial results
WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, resp...
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the ...
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis ...
Ionis to hold fourth quarter and full year 2023 financial results webcast
Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
MARSEILLE, France--(BUSINESS WIRE)--Vect-Horus announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).
Ionis Pharma's genetic disease drug succeeds in late-stage study
Ionis Pharmaceuticals said on Monday its therapy for the treatment of a rare genetic disease met the main goal in a late-stage trial.
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks Donidalorsen demonstrat...